Originally published In Press as doi:10.1074/jbc.M002608200 on June 2, 2000
J. Biol. Chem., Vol. 275, Issue 33, 25207-25215, August 18, 2000
Regulation of Connexin Degradation as a Mechanism to Increase Gap
Junction Assembly and Function*
Linda S.
Musil
,
Anh-Chi N.
Le,
Judy K.
VanSlyke, and
Lori M.
Roberts
From the Vollum Institute for Advanced Biomedical Research, Oregon
Health Sciences University, Portland, Oregon 97201
Received for publication, March 27, 2000, and in revised form, May 10, 2000
 |
ABSTRACT |
Connexins, the integral membrane protein
constituents of gap junctions, are degraded at a rate
(t1/2 = 1.5-5 h) much faster than most other cell
surface proteins. Although the turnover of connexins has been shown to
be sensitive to inhibitors of either the lysosome or of the proteasome,
how connexins are targeted for degradation and whether this process can
be regulated to affect intercellular communication is unknown. We show
here that reducing connexin degradation with inhibitors of the
proteasome (but not with lysosomal blockers) is associated with a
striking increase in gap junction assembly and intercellular dye
transfer in cells inefficient in both processes under basal conditions.
The effect of proteasome inhibitors on wild-type connexin stability,
assembly, and function was mimicked by treatment of assembly-inefficient cells with inhibitors of protein synthesis such as
cycloheximide. Sensitivity of connexin degradation to cycloheximide,
but not to proteasome inhibitors, was abolished when connexins were
rendered structurally abnormal by perturbation of essential disulfide
bonds or by mutation. Our findings provide the first evidence that
intercellular communication can be up-regulated at the level of
connexin turnover and that a short-lived protein may be required for
conformationally mature connexins to become substrates of proteasomal degradation.
 |
INTRODUCTION |
Gap junctions are ordered arrays of intercellular plasma membrane
channels that directly link the cytosols of two adjoining cells. By
serving as low resistance pathways for the diffusional transfer of low
molecular weight substances such as ions, amino acids, and second
messengers, gap junctions play important roles in embryonic
development, growth control, and the function of differentiated tissues
throughout the body (1). In vertebrates, gap junctions are composed of
members of a highly homologous family of tetraspanning integral
membrane proteins known collectively as connexins. The first step in
the assembly of gap junctions is the noncovalent oligomerization of six
connexin monomers into an annular structure known as a connexon, or
hemichannel (2). After transport to the cell surface, two connexons on
apposing cell surfaces dock to form an intercellular channel. These
channels then cluster at densities up to 10,000/µm2 into
paracrystallin arrays referred to as gap junctional "plaques," each
of which can contain from ~10 to more than 10,000 intercellular channels. To date, no nonconnexin protein has been demonstrated to be a
component of gap junctional plaques or to be essential for gap junction assembly.
One of the most unusual aspects of gap junction biosynthesis is the
exceptional metabolic lability of connexins. As assessed from the
degradation rate of total cell surface biotinylated proteins, the
half-life of the great majority of plasma membrane proteins exceeds
24 h (3). In contrast, pulse-chase analysis has demonstrated that
connexin family members turn over with a half-life of only 1.5-5 h,
even after incorporation into gap junctional plaques. This rapid rate
of degradation has been observed in a wide variety of mammalian systems
including primary and established tissue culture cells (4, 5), whole
organs (6), and intact animals (7). The instability of connexins is
especially remarkable given the relatively long half-lives of
components of the tight junction (8) and of desmosomes (9), and because
intercellular communication can be rapidly down-regulated by gating of
the gap junctional channel without the need for connexin degradation.
To date, two proteolytic pathways have been implicated in connexin
turnover in intact cells. The first is the lysosome, which electron
microscopy localization studies have shown mediates the degradation of
internalized gap junctional plaques in at least some cell types (10).
The second is the proteasome, the multicatalytic protease complex that
degrades most fast turnover proteins in the cytosol and nucleus and
that also plays a role in the degradation of proteins in the secretory
pathway. Laing and colleagues (6, 11, 12) have reported that chemical
inhibitors of the proteasome decrease the rate of turnover of
connexin43 (Cx43)1 in tissue
culture cells (11, 12) and in intact heart (6) as determined by
pulse-chase analysis. We have recently obtained similar results for
another member of the connexin family, connexin32 (Cx32) (13).
Experiments in which brefeldin A was used to block intracellular
transport suggested that proteasome inhibitor-sensitive degradation of
connexins occurs at the level of the ER (13) as well as after transport
to the cell surface (12). Both sites have previously been implicated in
proteasome-mediated degradation of other integral plasma membrane
proteins (14). In none of the aforementioned studies were the
consequences of proteasome inhibition on gap junction function assessed.
Although highly unusual for an integral plasma membrane protein, rapid
turnover kinetics are a common characteristic of mature, fully folded
forms of cytoplasmic and nuclear proteins involved in signal
transduction. Before such proteins can be degraded by the proteasome,
they must undergo a multistep targeting process. First, the substrate
is usually distinguished from other wild-type molecules by
posttranslational "tagging" events such as a change in
phosphorylation and/or protein-protein interaction that facilitate the
addition of polyubiquitin chains and mark it for destruction (15). The
substrate must then be completely unfolded to gain entry into the
proteolytic chamber of the 20S proteasome core, a process that for at
least some proteins appears to require extraproteasomal components such
as cytosolic molecular chaperones (16). Decreasing the efficiency with
which cytosolic and nuclear proteins are targeted for proteasomal
degradation is a physiologically important mechanism by which their
signaling function is prolonged or enhanced (17). For example,
regulated proteasomal degradation of the cytosolic enzyme ornithine
decarboxylase requires association with a protein known as antizyme.
Preventing antizyme synthesis with cycloheximide stabilizes ornithine
decarboxylase and preserves its enzymatic function (18, 19). Although
the mechanism is not yet clear, protein synthesis inhibitors also slow
the turnover and thereby prolong the activity of certain other (but not
all) cytoplasmic proteasome substrates, including pp60v-src
(20), estradiol-liganded estrogen receptors (21), and some forms of p53
(22).
The objective of the current study was to determine whether the
signaling function of integral membrane connexins (intercellular communication) could be increased by slowing the rate of connexin turnover. We show here that reducing connexin degradation with inhibitors of the proteasome or of protein synthesis (but not with
inhibitors of the lysosome) is associated with a striking increase in
gap junctional plaque assembly and intercellular dye transfer in cells
that are inefficient in both processes under basal conditions. Our
findings support a model in which protein synthesis inhibitors
interfere with events required for targeting of folded forms of
connexins for proteasomal degradation, possibly by lowering the levels
of a fast-turnover protein required for this process. Regulation of the
rate of connexin degradation is a novel means of posttranslationally
increasing intercellular communication that is distinct from gating of
the gap junctional channel.
 |
EXPERIMENTAL PROCEDURES |
Cell Culture
--
Mouse sarcoma cells stably transfected with
the adhesion molecule L-CAM (S180L cells) (23), NRK fibroblasts,
and L929 fibroblasts were cultured in DMEM plus 10% FCS, penicillin G,
and streptomycin as described previously (4). CHO-K1 cells were
maintained in F-12 medium with the same additions and were refed with
fresh medium 6-8 h prior to use. Three-day-old, newly confluent
cultures were used for all experiments unless otherwise specified.
Serum-starved S180L (ssS180L) cells were generated by rinsing 2-day-old
S180L cultures three times with serum-free F-12 medium and culturing the cells in the same medium for 8-12 h prior to use. Clonal lines of
PC12J cells (a subclone of rat pheochromocytoma cells devoid of
endogenous gap junction activity) stably expressing either wild-type
human Cx32 or a CMTX-linked Cx32 mutant were generated and maintained
in RPMI 1640 medium supplemented with 10% horse serum, 5% FCS,
penicillin G, streptomycin, and 400 µg/ml G418 as described by
Deschenes et al. (24).
Antibodies and Reagents--
Anti-Cx43 antibodies were affinity
purified from a rabbit antiserum generated against a synthetic peptide
encoding amino acids 252-271 of rat Cx43 (4) using a glutathione
Sepharose-immobilized recombinant fusion protein consisting of
glutathione-S-transferase linked to residues 229-382 of rat Cx43. Cx32
was immunoprecipitated with a crude antiserum from rabbits immunized
with a synthetic peptide corresponding to amino acids 98-124 of rat
Cx32 (kindly provided by D. Goodenough, Harvard Medical School, Boston,
MA) (25). Unless otherwise noted, all other reagents were from Sigma except for carboxybenzyl-leucyl-leucyl-leucine-vinylsulfone
(ZL3VS), a gift of M. Bogyo (Harvard Medical School). Final
concentrations of reagents in experiments were as follows: 100 µM N-acetyl-leu-leu-norleucinal (ALLN),
10 µM lactacystin, 20 µM ZL3VS,
100 µg/ml leupeptin, 200 µM chloroquine, 2 mM dithiothreitol (DTT), and 20 µg/ml cycloheximide. At
this concentration, cycloheximide reduced the synthesis of total
cellular proteins (including connexins) by >96% within 10 min (not shown).
Immunofluorescence Microscopy--
Cells grown on glass
coverslips were fixed in 2% paraformaldehyde in phosphate-buffered
saline (PBS) (pH 7.5) for 30 min at room temperature, rinsed for 30 min
with PBS, and then postfixed for 5 min with
20 °C acetone. After a
second 30-min rinse with PBS, the cells were incubated for 30 min in
PBS supplemented with 0.5% normal goat serum, 0.1% bovine
serum albumin, 0.2% Triton X-100, and 0.02% sodium azide. Cells were
sequentially incubated with anti-Cx43 antibodies and then with
rhodamine-conjugated goat anti-rabbit IgG (Pierce) as described by Le
and Musil (26). The coverslips were mounted onto glass slides with
MOWIOL 4-88 mounting medium (Calbiochem) and immunofluorescence images
captured using a Leica DM LD photomicrography system and Scion Image
1.60 software.
Scrape Loading/Dye Transfer Assay of Gap Junctional Intercellular
Communication--
Cells grown on 5-mm-diameter glass coverslips were
rinsed three times with Hanks' balanced salt solution containing 1%
bovine serum albumin (HB). The HB was removed and 2.5 µl of PBS
containing 1% Lucifer Yellow (LY) (Sigma) and 0.75% of the gap
junction-impermeant compound rhodamine dextran (fluoro-ruby; molecular
mass, 10 kDa) (Molecular Probes) was applied to the center of
the glass coverslip. A 27 gauge needle was then used to create two
longitudinal scratches through the cell monolayer. Cells were incubated
in the dye mix for exactly 1 min and then quickly rinsed three times
with HB prior to a 5-min incubation in HB at room temperature to allow dye transfer. The cells were rinsed three times with PBS and
immediately fixed for 30 min at room temperature with 2%
paraformaldehyde/PBS, pH 7.5. LY and rhodamine dextran were
subsequently examined by fluorescence microscopy (Leitz DMR) using
fluorescein and rhodamine filter sets, respectively. Only images taken
with fluorescein optics are shown; in all cases, rhodamine dextran
remained confined to a single row of cells immediately bordering the
wound. In some experiments, 1% biocytin (Molecular Probes) was
substituted for LY and visualized with avidin-FITC (Molecular Probes)
as described by Le and Musil (26). The scrape loading/dye transfer
assay has the advantage over microinjection techniques of allowing
simultaneous monitoring of dye coupling in a large population of cells;
its utility in the assessment of gap junction-mediated
intercellular communication has been well documented (27, 28).
Metabolic Labeling and Immunoprecipitation--
Cells were
starved for methionine for 30 min at 37 °C in DMEM lacking
methionine and supplemented with 5% dialyzed FCS and 2 mM
glutamine ("labeling" medium). The medium was then replaced with
fresh labeling medium containing [35S]methionine
(Expre35S35S, NEN Life Science Products; 0.1 mCi/35-mm dish of cells, scaled proportionally for dishes of other
sizes). The radioactive medium was removed after a 30-min pulse, and if
desired, the cells were then rinsed three times with complete DMEM
supplemented with 0.5 mM unlabeled methionine and chased in
DMEM/0.5 mM unlabeled methionine/10% FCS at 37 °C. At
the end of the chase period, cells were rinsed once with PBS at 4 °C
and resuspended in lysis buffer (5 mM Tris base, 5 mM EDTA, 5 mM EGTA, 10 mM
iodoacetamide, 2 mM phenylmethylsulfonyl fluoride, pH 8.0)
supplemented with 0.6% SDS, 250 mg/ml soybean trypsin inhibitor, and
200 µM leupeptin. The cell lysates were then
immunoprecipitated with the desired antibody as described by Le and
Musil (26). Two modifications were made for immunoprecipitation of
Cx32: first, cells were lysed in SDS at room temperature for 30 min
instead of at 100 °C for 3 min to minimize aggregation of Cx32; and
second, samples were precleared with protein A-Sepharose for 2 h
at 4 °C prior to addition of anti-Cx32 antibody (29). Cx43 and Cx32
immunoprecipitates were analyzed on 10 or 11% SDS-polyacrylamide gel
electrophoresis gels, respectively, after incubation of samples in
SDS-polyacrylamide gel electrophoresis sample loading buffer for either
3 min at 100 °C (Cx43) or 30 min at room temperature (Cx32). The
dried gels were quantitated on a PhosphorImager 445 SI (Molecular
Dynamics, Inc.) utilizing IPLab Gel software (Signal Analytics
Corp.).
Pulse-Chase Analysis of Cx43 in Newly Forming S180L Cell
Monolayers--
S180L cells were grown in 100-mm tissue culture dishes
in DMEM/10% FCS until ~80% confluent. After two rinses with
PBS lacking Ca+2 and Mg+2 (PBS-), the cultures
were incubated in PBS-, 5 mM EDTA, and 2% FCS for 10 min
at room temperature on a orbital shaker. The cells were then removed
from the plate and triturated 10 times with a 10-ml pipette to generate
a single-cell suspension. The cells were pelleted at 150 × g for 7 min and resuspended in labeling medium (see above).
After verification of cell viability (>95% Trypan blue-excluding) and
the absence of cell clumps, 5 × 105 cells in 500 µl
of labeling medium were added to each well of a 12-well tissue culture
plate. Label (60 µCi of Expre35S35S/well) was
then immediately added, and the cells were incubated at 37 °C for 30 min, during which time the cells quantitatively adhered to the dish.
The cultures were then rinsed three times with complete DMEM
supplemented with 0.5 mM unlabeled methionine and chased
for the desired period prior to cell lysis and immunoprecipitation of
Cx43 as described above.
 |
RESULTS |
Cell Type-specific Differences in Gap Junction Assembly
Competence--
A striking feature of gap junction biosynthesis both
in vivo and in tissue culture is that cells differ greatly
in their inherent ability to assemble connexins into gap junctional
plaques. The four cell lines shown in Fig.
1 synthesize comparable quantities of
endogenously expressed, wild-type Cx43, the coding sequence of which is
very highly conserved among mammals and not subject to alternative
mRNA splicing. We have previously shown that each cell type
assembles this Cx43 into connexons and transports them to the cell
surface (30, 31). However, under basal conditions, only NRK and S180L
cells are able to efficiently assemble Cx43 into large gap junctional
plaques, which appear as punctate or linear concentrations of
anti-connexin immunoreactivity at cell-cell interfaces (Fig. 1,
A and C). CHO cells have substantially fewer and
generally smaller gap junctions (Fig. 1E; see also Figs.
5A and 7A), even if the level of Cx43 expression
is increased by refeeding the cells in fresh culture medium for 6-8 h
(data not shown). At the resolution of immunofluorescence microscopy,
L929 fibroblasts lack detectable gap junctions (Fig. 1G).
The number of immunodetectable gap junctions in NRK, S180L, CHO, and
L929 cells correlates closely with their capacity to mediate
intercellular communication as assessed by a scrape loading/dye
transfer assay. As previously reported (4), NRK and S180L cells are
highly communication-competent and transfer LY to several orders of
cells distal to the wound edge (Fig. 1, B and D).
Intercellular movement of LY is still detectable but much more
restricted in CHO cells (Fig. 1F), whereas the dye remains
confined to wounded cells in monolayers of L929 fibroblasts (Fig.
1H). Based on their capacity to assemble functional gap
junctions under basal conditions, we herein refer to cells as
either "assembly-efficient" (e.g. NRK and S180L cells),
"assembly-inefficient" (e.g. CHO cells), or "assembly-incompetent" (e.g. L929 cells).

View larger version (48K):
[in this window]
[in a new window]
|
Fig. 1.
Three gap junction assembly phenotypes.
Confluent monolayers of NRK, serum-maintained S180L, CHO, and L929
cells were either fixed and immunostained with anti-Cx43 antibodies
(top row) or assessed for their ability to carry out gap
junction-mediated intercellular transfer of LY as described under
"Experimental Procedures" (bottom row).
|
|
Assembly and Turnover of Cx43 during Initial Establishment of Gap
Junctional Plaques--
Despite their differences in gap junction
phenotype, each of the four cell lines shown in Fig. 1 degrades Cx43
with a t1/2 of only ~1.5-4 h as assessed by
pulse-chase analysis of confluent cell monolayers (4, 11). These
kinetics are in keeping with results obtained in other systems with
high levels of preexisting intercellular contact (5-7, 32). One
possibility not addressed by such experiments is that the first gap
junctional plaques assembled at newly established cell-cell contacts
might be metabolically stable and that there are a limited number of
such stable gap junctions that can be accommodated at cell interfaces.
If so, then any [35S]methionine-labeled Cx43 synthesized
in confluent cultures of gap junction-rich cells after saturation is
reached would be turned over at a rate indistinguishable from that of
connexins in less assembly-competent cells. Differential cell surface
stability has been described for the nicotinic acetylcholine receptor,
which has a t1/2 of 8-10 days when localized to the
neuromuscular junction but only 1 day at extrajunctional sites (33,
34). To test whether the extent of preexisting intercellular contact
influences Cx43 assembly and/or turnover, pulse-chase studies were
conducted in both established and newly forming monolayers of S180L
cells. In 2-day-old, confluent cultures, pulse-labeled
[35S]methionine-Cx43 underwent the posttranslational
changes in electrophoretic mobility characteristic of Cx43 in
assembly-efficient cells (4) (Fig.
2A). Following synthesis as a
42-kDa species referred to as Cx43-NP,
[35S]methionine-Cx43 was progressively converted to two
slower migrating species, Cx43-P1 and Cx43-P2,
by phosphorylation on serine residues. Numerous studies in a wide
variety of systems, including S180L cells, have established that
conversion to the P1 and P2 forms occurs only
after transport to the cell surface and that Cx43-P2 is
concentrated in gap junctional plaques (30, 32, 35). All forms of
[35S]methionine-Cx43 were largely turned over by 8 h
of chase (Fig. 2A, lane 4). To examine Cx43 processing
during de novo formation of cell-cell contacts, S180L cells
were dissociated into a single-cell suspension under protease-free
conditions and then replated at confluent density to rapidly reform a
monolayer. [35S]Methionine-Cx43 synthesized during the
initial 30-min replating period was converted to the plaque-associated
P2 form at a rate that closely correlated with the
appearance of gap junctions as assessed by immunofluorescence
microscopy (data not shown). The labeled Cx43 was degraded over an 8-h
period with kinetics nearly identical to those of Cx43 in two-day-old
monolayers (Fig. 2B). Similar results were obtained when
cells were pulsed 3 h after replating (not shown). The lack of a
detectable pool of metabolically stable Cx43 indicates that the
turnover rate of connexins is unaffected by the presence or absence of
preexisting gap junctional plaques.

View larger version (33K):
[in this window]
[in a new window]
|
Fig. 2.
Cx43 processing and turnover during de
novo formation of cell-cell contacts. A, a
confluent monolayer of S180L cells established over a 2-day period was
pulsed for 30 min with [35S]methionine and then chased
for 0, 1, 4, or 8 h. B, S180L cell cultures were
dissociated into a single-cell suspension under protease-free
conditions that inhibit the function, but preserve the structural
integrity, of calcium-dependent cell-cell adhesion
molecules. The cells were replated at confluent density in the presence
of [35S]methionine and after a 30-min labeling period
were chased for 0, 1, 4, or 8 h. After the chase period, all cells
were lysed, and Cx43 was analyzed by immunoprecipitation and
SDS-polyacrylamide gel electrophoresis. Exposure time was adjusted for
optimal visualization of [35S]methionine-Cx43 at the 8-h
time point. The percentage of pulse-labeled Cx43 remaining at this time
was 10% in replated cells (B, lane 4) and 16% in
established monolayers (A, lane 4). Cx43-NP,
Cx43-P1, and Cx43-P2 refer to differentially
phosphorylated forms of Cx43 (see text).
|
|
Effect of Inhibitors of the Proteasome and Lysosome on Cx43
Turnover--
As a first step toward determining whether a reduction
in the rate of connexin degradation influences gap junction assembly and/or function, we assayed inhibitors of either the proteasome or the
lysosome for their ability to decrease Cx43 turnover in NRK, S180L,
CHO, and L929 cells (Fig. 3). As
expected, only 9-25% of the Cx43 synthesized during a 30-min
pulse was recovered after a 7-h chase in the absence of inhibitors in
all four cell types. Although there was some variability between
experiments in the magnitude of the effect, the proteasome inhibitor
ALLN reproducibly (in 15 of 15 experiments) increased the amount of
labeled Cx43 that survived the chase period between 2- and 7-fold in
all cell types examined relative to untreated controls within the same trial. In a less extensive series of experiments, mechanistically distinct, highly selective inhibitors of the proteasome
(ZL3VS and lactacystin) (36) yielded similar results (data
not shown). The lysosomotropic amine chloroquine (CLQ) significantly
decreased Cx43 degradation in assembly-efficient NRK and S180L cells as well as in assembly-incompetent L929 cells. In contrast, CLQ only very
weakly reduced Cx43 turnover in assembly-inefficient CHO cells despite
its reported ability to block lysosome-mediated catabolism in this cell
type (37). A mechanistically distinct inhibitor of lysosomal
proteolysis, leupeptin, was also ineffective at concentrations (100 µg/ml) that reduce connexin degradation in other cell types (13)
(data not shown). Insensitivity of Cx43 degradation to lysosomal
inhibitors has been previously reported for a subclone of CHO cells by
Laing and Beyer (11). The susceptibility of Cx43 to proteasomal or
lysosomal inhibition therefore did not correlate with gap junction
assembly competence in the cell types tested.

View larger version (29K):
[in this window]
[in a new window]
|
Fig. 3.
Effect of inhibitors of the proteasome,
lysosome, and protein synthesis on the turnover of Cx43.
A, NRK, S180L, CHO, and L929 cells were metabolically
labeled for 30 min with [35S]methionine and then chased
at 37 °C for 7 h in unsupplemented chase medium (0) or in the
presence of an inhibitor of either the proteasome (100 µM
ALLN, 10 µM lactacystin, or 20 µM
ZL3VS), the lysosome (200 µM CLQ), or protein
synthesis (20 µg/ml CHX). Due to interexperimental (but not
intraexperimental) differences, the percentage of pulse-labeled
[35S]methionine-Cx43 recovered after a 7-h chase without
inhibitor ranged from 9 to 25% in each of the cell lines examined. To
permit comparison of results obtained in experiments with different
basal rates of Cx43 turnover, the data are presented as the fold
increase in the percentage of recovery of Cx43 after a 7-h chase in the
presence of inhibitor relative to the percentage of recovery of Cx43 in
cells in the same experiment chased in the absence of inhibitor.
B, plot of the percentage of pulse-labeled Cx43 remaining in
CHO cells after 0, 1, 3, and 7 h of chase in either the absence
(open circles) or presence of 100 µM ALLN
(closed circle), 200 µM CLQ (open
squares), or 20 µg/ml CHX (closed squares) in a
typical experiment. Note that the effect of ALLN and CHX on Cx43
degradation becomes significant after 1 h of chase, possibly reflecting
the time required for ALLN to maximally inhibit proteasome function in
intact cells and for CHX to reduce the levels of the putative
fast-turnover mediator of connexin turnover. An apparent break in the
linearity of [35S]methionine-Cx43 turnover in untreated
cells at later time points (after ~80% of pulse-labeled Cx43 has
been degraded) has previously been observed in rodent heart (6).
|
|
Inhibition of Proteasomal, but not Lysosomal, Degradation of Cx43
Is Associated with Up-regulation of Gap Junction Formation in
Assembly-inefficient Cells--
-We next tested whether the metabolic
stabilization of Cx43 caused by inhibitors of protein degradation was
associated with changes in the assembly and/or function of gap
junctions. The results obtained were dependent on the capacity of the
cells to form gap junctional plaques under basal conditions. NRK cells showed a small increase in the already very high number of gap junctional plaques after a 3-7-h treatment with any of the proteasome inhibitors tested (ALLN, ZL3VS, MG132, and lactacystin;
ALLN data shown in Fig. 4B).
Comparable results were obtained with assembly-efficient S180L cells
and primary chick lens epithelial cells (not shown), consistent with
previous reports that these reagents modestly enhance plaques in other
intrinsically gap junction-rich cell types (12, 6). The lysosomal
inhibitor CLQ did not increase the number of immunodetectable junctions
in NRK, S180L, or lens epithelial cells. Instead, Cx43 staining
accumulated intracellularly in vesicles with the swollen appearance
characteristic of endosomal/lysosomal compartments after neutralization
of their lumenal pH by this lysosomotropic amine (Fig. 4C,
arrowhead). None of the proteasomal (ALLN; Fig.
4E) (ZL3VS, MG132) or lysosomal (CLQ; Fig.
4F) (leupeptin) inhibitors tested induced detectable gap
junction formation or function in assembly-incompetent L929 cells.

View larger version (39K):
[in this window]
[in a new window]
|
Fig. 4.
Effect of protein degradation inhibitors on
gap junction formation in assembly-efficient and assembly-incompetent
cells. Assembly-efficient NRK cells or assembly-incompetent L929
cells were stained for Cx43 after a 7-h incubation in unsupplemented
medium (A and D) (0) or in the
presence of 100 µM ALLN (B and E)
or 200 µM chloroquine (C and
F).
|
|
A fundamentally different result was obtained with assembly-inefficient
cells. Incubation of CHO cells with any of the four proteasomal
inhibitors tested (ALLN, ZL3VS, lactacystin; MG132) induced
a large increase in the number of immunocytochemically detectable gap
junctions over a 3-6-h period (ALLN data shown in Fig.
5B). Up-regulation of plaques
in CHO cells was associated with a correspondingly large increase in
dye coupling as assessed by scrape loading/dye transfer analysis (Fig.
5E). Intercellular transfer of LY or biocytin was inhibited
by pretreatment of cells with the gap junction blocker
18
-glycyrrhetinic acid (
GA) and was not observed for
junction-impermeant rhodamine-dextran, demonstrating a bona
fide increase in gap junction-mediated intercellular communication (data not shown). In contrast, the lysosomal inhibitors CLQ (Fig. 5,
C and F) and leupeptin (not shown) induced
neither gap junction assembly nor function.

View larger version (82K):
[in this window]
[in a new window]
|
Fig. 5.
Proteasome inhibition up-regulates gap
junctions in assembly-inefficient cells. CHO cells and ssS180L
cells were incubated for 7 h in new medium without additions
(A, D, G, and J), with 100 µM ALLN
(B, E, H, and K), or with 200 µM
chloroquine (C, F, I, and L). The cells were then
either fixed and immunostained with anti-Cx43 antibodies
(A-C and G-I) or assessed for their ability to
mediate intercellular transfer of the gap junction permeant LY
(D-F and J-L).
|
|
Up-regulation of gap junctions in CHO cells in response to proteasome
inhibitors could either be coincidentally or causally related to their
assembly-inefficient phenotype under basal conditions. Evidence in
support of the latter possibility was obtained in experiments in which
the ability of S180L cells to assemble gap junctions was modulated by
changing their culture conditions. We have empirically found that
overnight incubation of S180L cells in the absence of serum greatly
reduces the number of morphologically or functionally detectable gap
junctions despite the continued synthesis of Cx43 and the cell-cell
adhesion molecule LCAM. Treatment of such ssS180L cells with proteasome
inhibitors for 3-6 h in either the absence or presence of new 10% FCS
resulted in a large increase in functional gap junctions (Fig. 5,
H and K) similar to that observed in CHO cells.
Serum starvation therefore converted S180L cells from an
assembly-efficient to an assembly-inefficient phenotype and
concomitantly conferred the ability to up-regulate gap junctions in
response to proteasome inhibitor treatment. Despite their efficacy in
reducing the turnover of pulse-labeled Cx43 (Fig. 3A),
lysosomal inhibitors (CLQ and, not shown, leupeptin) induced neither
gap junction assembly nor activity in ssS180L cells (Fig. 5,
I and L).
The Effect of Proteasome Inhibitors on Gap Junction Formation Is
Mimicked by Inhibitors of Protein Synthesis--
Degradation of
properly folded cytosolic or nuclear proteins by the
ubiquitination/proteasome system usually requires that the substrate
undergo one or more regulatable targeting events that distinguish it
from other mature proteins (15, 19). To investigate whether such a
mechanism might also control proteasome-mediated degradation of
connexins, we tested agents known to block the targeting and therefore
the turnover of other proteins for their effect on connexins. Among the
compounds assayed, only protein synthesis inhibitors significantly and
reproducibly (in 29 of 29 experiments) reduced the rate of
pulse-labeled Cx43 degradation. As shown in Fig.
6, addition of 20 µg/ml cycloheximide
(CHX) to the chase medium of NRK, S180L, CHO, or L929 cells increased
the amount of [35S]methionine-Cx43 recovered after a 7-h
chase between 2.6- and 5.7-fold relative to untreated control cells
within the same experiment (results of four independent experiments,
quantitated in Fig. 3A). The ability of CHX to enhance the
recovery of Cx43 was optimal at concentrations that inhibited protein
synthesis >90% and was reversible by incubation in CHX-free medium.
Moreover, synthesis-blocking quantities of the mechanistically and
structurally distinct protein synthesis inhibitors puromycin and
anisomycin had a similar effect (data not shown). Inhibition of protein
synthesis rather than some other property of CHX therefore appears to
account for its enhancement of connexin stability. There was no
significant reproducible difference among the cell types tested in the
extent to which CHX decreased Cx43 turnover.

View larger version (38K):
[in this window]
[in a new window]
|
Fig. 6.
Cycloheximide reduces the turnover of
Cx43. CHO, L929, NRK, and serum-maintained S180L cells were
pulse-labeled for 30 min with [35S]methionine and then
chased for 7 h in either the absence (lanes 2, 6, 10, and 13) (cont, control) or presence (lanes
3, 7, 11, and 14) of 20 µg/ml CHX prior to
immunoprecipitation of Cx43 and analysis by SDS-polyacrylamide gel
electrophoresis. Cx43 immunoprecipitates from pulse-labeled CHO and
L929 cells chased in the presence of 100 µM ALLN are
included for comparison (lanes 4 and 8). The
asterisk indicates the gap junctional plaque-associated
P2 phosphoform of Cx43.
|
|
As shown in Fig. 3, the effect of CHX on Cx43 turnover was comparable
to that of the proteasomal inhibitor ALLN. Moreover, both compounds
shared the ability to induce phosphorylation of Cx43 to the
Cx43-P2 species in CHO cells but not in
assembly-incompetent L929 fibroblasts (Fig. 6). Given the close
correlation between modification of Cx43 to the P2 form and
assembly of functional gap junctional plaques (30, 32, 35), we tested
whether protein synthesis inhibitors also selectively up-regulated gap
junctions in assembly-inefficient cells (Fig.
7). Incubation of CHO cells with 20 µg/ml CHX resulted in an increase in the number of immunologically detectable gap junctional plaques over a 4-7-h period despite the lack
of new connexin synthesis (Fig. 7C). Importantly, the increase in plaques was accompanied by a corresponding up-regulation of
gap junction-mediated intercellular dye coupling (Fig. 7D). Protein synthesis-blocking concentrations of CHX or (not shown) anisomycin also increased the level of functional gap junctions in
assembly-inefficient ssS180L cells (Fig. 7, G and
H). As was the case with proteasome inhibitors, CHX and
other protein synthesis inhibitors failed to induce detectable gap
junction formation or function in assembly-incompetent L929 cells after
2-8 h of treatment (data not shown). With regard to assembly-efficient cells, CHX did not notably up-regulate gap junctions in NRK cells between 3-10 h of treatment but instead modestly decreased both gap
junction number and intercellular dye coupling after extended (6-10 h)
incubations (Fig. 7, K and L). Similar results
were obtained with assembly-efficient primary lens epithelial cells and
serum-maintained S180L cells. Potential reasons for the difference in
the effect of proteasome inhibitors and protein synthesis blockers on
assembly-efficient cells are addressed under "Discussion."

View larger version (46K):
[in this window]
[in a new window]
|
Fig. 7.
Cycloheximide up-regulates gap junction
formation and function in assembly-inefficient, but not
assembly-efficient, cells. CHO cells, ssS180L cells, and NRK
fibroblasts were incubated for 7 h in new medium with or without
20 µg/ml CHX. A, C, E, G, I, and K, anti-Cx43
immunostaining. B, D, F, H, J, and L, scrape
loading analysis of gap junctional intercellular communication.
|
|
Protein Synthesis Inhibitors Do Not Affect the Degradation of
Misfolded Connexins--
The results presented above are consistent
with the possibility that inhibition of protein synthesis reduces
targeting (tagging and/or unfolding) of connexins for destruction by
the proteasome (possibility 1), but they do not rule out the
possibility that CHX acts instead by somehow interfering with
proteasome-mediated hydrolysis of connexins after their unfolding
(possibility 2) or by inhibiting a degradation pathway that mimics but
is not causally related to the proteasome (possibility 3). To
distinguish between these three alternatives, we compared the effect of
inhibitors of the proteasome or of protein synthesis (ALLN and CHX,
respectively) on the turnover of nonnative forms of connexins. Our
rationale was that the tagging of a protein for proteasomal destruction as well as the ease with which it is unfolded is influenced by its
conformational state, whereas its hydrolysis after linearization is
not. A change in the sensitivity of degradation of misfolded connexins
to CHX but not to ALLN would therefore be consistent with the first,
but not the second, possibility; a loss in the ability of ALLN, but not
of CHX, to inhibit the turnover of misfolded connexins would indicate
that CHX is affecting a process independent of the proteasome
(possibility 3). The degradation of two types of improperly folded
connexin molecules was examined (Fig. 8). First, Cx43 was synthesized and chased in CHO cells in the continuous presence of 2 mM DTT, which abolishes the formation of the
highly conserved intramolecular disulfide bonds that are essential for connexin function (38). Although degradation of DTT-unfolded Cx43
remained sensitive to proteasome inhibitors, CHX had virtually no
effect on this process whereas turnover of Cx43 in control (no DTT)
cells was effectively reduced by both ALLN and CHX (Fig. 8A). Given the multiple effects of DTT, it was, however,
conceivable that the reducing agent affected Cx43 turnover indirectly
instead of by altering connexin conformation. To control for this
possibility and to extend our findings to another member of the
connexin family, we also examined the effect of inhibitors of protein
synthesis and of the proteasome on the degradation of wild-type and
mutant forms of Cx32 expressed in stable PC12 cell transfectants (24, 13). Wild-type Cx32 in PC12 cells was degraded at the rapid rate
characteristic of the connexin family in a process sensitive to
proteasome inhibitors as well as to CHX. In the typical experiment shown in Fig. 8B, CHX increased the amounts of pulse-labeled
wild-type Cx32 and ALLN that survived a 6-h chase by 4.8- and 3.8-fold, respectively, over the untreated control in lane 2. We have
previously reported that three nonfunctional point mutants of Cx32
(E208K, R142W, and E186K Cx32) linked to the human peripheral
neuropathy Charcot-Marie-Tooth X disease are unable to assemble into
connexons and have defects in intracellular transport indicative of
conformational abnormalities (13). Degradation of each of these three
Cx32 mutants was sensitive to proteasome inhibitors (Fig. 8B,
lanes 8, 12, and 16) but was not reduced by CHX
(lanes 7, 11, and 15). CHX also caused the loss
of all immunofluorescently detectable E186K, E208K, and R142W Cx32 (but
not of wild-type Cx32) within a 6-h period, indicating that sensitivity
to CHX is a property of the total cellular pool of mutant Cx32 and not
just the fraction that incorporates [35S]methionine
during a 30-min pulse (data not shown). Given that each mutation is in
a different domain of Cx32 and confers a distinct intracellular
localization, the lack of effect of CHX on mutant turnover cannot be
due to the loss of a specific amino acid residue or to retention in a
particular subcellular compartment. Instead, misfolding of connexin
molecules, induced by either DTT or mutation, appears to account for
the loss of sensitivity to CHX. These findings support a model in which
proteasomal degradation of native, but not of misfolded, connexins
involves a CHX-sensitive step that targets them for proteasomal
destruction. The fact that Cx43 and Cx32 show comparable responses to
proteasomal and protein synthesis inhibitors despite their low sequence
similarity (relative to other connexins) makes it likely that this
model will apply to additional members of the connexin family.

View larger version (31K):
[in this window]
[in a new window]
|
Fig. 8.
Degradation of misfolded connexins is
sensitive to inhibitors of proteasomal degradation but not to protein
synthesis inhibitors. A, CHO cells endogenously
expressing wild-type Cx43 were pulse-labeled for 30 min with
[35S]methionine and then chased at 37 °C for 6 h
in unsupplemented chase medium or in the presence of the proteasome
inhibitor ALLN (100 µM) or 20 µg/ml CHX. In +DTT cells,
both the pulse and chase media contained 2 mM DTT. The data
are presented as the fold increase in the recovery of
[35S]methionine-Cx43 after a 6-h chase in the presence of
either ALLN or CHX relative to the percentage of recovery of
[35S]methionine-Cx43 in the absence of inhibitor (17%
-DTT, 6% +DTT). Shown is a representative data set from three
independent experiments. B, stable PC12 cell transfectants
expressing either wild-type Cx32 or the R142W, E186K, or E208K Cx32
mutant were labeled for 30 min with [35S]methionine and
then chased for 6 h in unsupplemented chase medium (lanes 2, 6, 10, and 14) or in the presence of 20 µg/ml CHX
(lanes 3, 7, 11, and 15) or 100 µM
ALLN (lanes 4, 8, 12, and 16).
|
|
 |
DISCUSSION |
In vivo as in tissue culture, cells range from
assembly-efficient (e.g. hepatocytes and cardiac
myocytes) to assembly-incompetent (e.g. some tumor cells)
(39) in their ability to oligomerize endogenously expressed, wild-type
connexins into gap junctional plaques. Some cell types with relatively
low levels of gap junction plaques can be operationally defined as
assembly-inefficient and are able to dramatically up-regulate gap
junction formation and function on a rapid time scale. This latter
category includes precompaction eight-cell stage blastomeres (40) and
day 21 pregnant rat myometrial smooth muscle cells (41), in which
increased intercellular communication is thought to play an important
role in embryonic development and parturition, respectively. A
molecular understanding of up-regulation of gap junction formation and
function in assembly-inefficient cells is therefore of relevance to a
variety of physiological processes. In this study, we have investigated whether decreasing the remarkably rapid turnover rate of connexins (t1/2 = 1.5-5 h) can serve as a mechanism to
increase gap junction formation and function. We found that lysosomal
inhibitors (CLQ and leupeptin) slowed the degradation of Cx43 in a cell
type-specific manner but did not up-regulate gap junction assembly or
dye coupling in any of the lines tested, as expected given that these
compounds prevent proteolysis within, but not transport to, the
endosome/lysosome system (37). In contrast, we found that inhibitors of
the proteasome strongly decreased connexin degradation in all of the
cell types examined. Most significantly, proteasome inhibition resulted
in a striking up-regulation of Cx43 phosphorylation, gap junction
formation, and intercellular dye coupling in previously
assembly-inefficient cell types. These findings provide the first
evidence that cell-cell communication can be up-regulated at the level
of connexin turnover. Moreover, they distinguish connexins from several
other types of integral plasma membrane proteins (including the cystic
fibrosis transmembrane conductance regulator), the degradation of which is reduced by proteasome inhibitors without increasing the functional pool of the protein on the cell surface (42, 43).
Physiologically, degradation of cytosolic and nuclear proteins is
down-regulated by preventing tagging events that serve to facilitate
recognition of the substrate by the ubiquitination/proteasomal machinery (15, 17). For ornithine decarboxylase, as well as several
other cytosolic regulatory molecules, an essential step in the
targeting process is physical association with another protein.
Polyamine-stimulated degradation of ornithine decarboxylase is blocked
if synthesis of its tagging protein (antizyme) is prevented with CHX
(18, 19). In an analogous process, CHX is thought to inhibit the
proteasome-mediated degradation of iron regulatory protein 2 in
iron-rich hepatoma cells by reducing the levels of an as yet unknown
short-lived tagging protein (44). We show here that CHX and other
general inhibitors of protein synthesis also reduce the degradation of
wild-type Cx43 and Cx32 to an extent comparable to that obtained with
direct inhibitors of the proteasome. Moreover, both classes of
inhibitors up-regulate gap junction formation and function in
assembly-inefficient (but not in assembly-incompetent) cell types.
Proteasome inhibitors do not block protein synthesis and, conversely,
protein synthesis inhibitors are not general perturbants of proteasomal
function as evidenced by the lack of effect of CHX on the degradation
of several well characterized proteasomal substrates (45-47). The
similarity in the effect of inhibitors of protein synthesis and of the
proteasome on connexins must therefore either be a mechanistically
unrelated coincidence or reflect a specific requirement for ongoing
protein synthesis in the proteasomal degradation of wild-type
connexins. Our data support the second interpretation for the following
reasons. First, the effects of proteasome inhibitors and CHX on gap
junctions are not additive (data not shown), consistent with the
possibility that they act on the same pathway rather than on two
independent processes. Second, although protein synthesis inhibitors,
including CHX, have been reported to interfere with lysosomal function
by an unknown mechanism (48), such an activity cannot account for their
effect on connexin turnover given that standard lysosomal inhibitors
only very weakly reduced Cx43 degradation in CHO cells despite the
sensitivity of this process to CHX. Third, we are not aware of any
nonproteasomal, nonlysosomal proteolytic system that might degrade
connexins that requires ongoing protein synthesis. Fourth, rendering
connexins conformationally abnormal by either reduction of disulfide
bonds or by mutation eliminates the effect of CHX (but not of
proteasome inhibitors) on connexin turnover, in keeping with the known
sensitivity of proteasomal targeting processes to substrate
conformation. One possibility is that the fast-turnover protein binds
directly to mature connexins and, analogous to antizyme in ornithine
decarboxylase degradation, targets connexins for proteasome-mediated,
but ubiquitin-independent, degradation. Given the role of ubiquitin in
the turnover of many proteasome substrates (49), an alternative
possibility not addressed in this study is that the short-lived protein
is involved in polyubiquitination, either of connexins themselves or of
proteins that (when modified) facilitate targeting to the proteasome
(50). It is also conceivable that CHX reduces the amount of a protein
involved in unfolding connexins for insertion into the catalytic
chamber of the proteasome and that conformationally abnormal,
unaggregated (13) connexins require less of this activity than mature,
stably folded connexin species. This scenario would be in keeping with
the finding that unfolding can be the rate-limiting step in the
proteasomal degradation of mature proteins and that a major cytosolic
chaperone implicated in this process (HSP70) is a fast-turnover protein
(16). Implicit in either model is that the putative short-lived
targeting protein can distinguish between different conformational
states of the connexin molecule. Precedence for this type of
interaction is provided by the proteasome-mediated degradation of the
estrogen receptor, which is sensitive to CHX or puromycin when it is
liganded to estradiol but not when it adopts a different conformation
upon binding the antiestrogen RU 58668 (51).
How could inhibition of connexin degradation by the proteasome elicit
the cell type-specific differences in gap junction formation that we
have observed? NRK, S180L, CHO, and L929 cells all synthesize wild-type
Cx43 of comparable metabolic stability that is assembled into connexons
and transported to the cell surface. The difference in the number of
gap junctions expressed by these cells under basal conditions therefore
appears to reflect dissimilarities in their intrinsic ability to
assemble connexons into gap junctional plaques. We have shown that
serum-maintained S180L cells form gap junctions shortly after being
replated at confluent density (Fig. 2), consistent with the
observations of Rook et al. (52) that cultured cardiac
myocytes establish functional gap junctional channels within 2-20 min
of initiating cell-cell contact. We propose that the rate and
efficiency with which cell surface Cx43 is incorporated into plaques in
these and other assembly-efficient cells is such that almost all of the
cell-cell contact area available for gap junctions becomes occupied
under basal conditions. Increasing the total amount of connexin protein
with proteasome inhibitors therefore induces only a minor enhancement
in the number of gap junctional plaques, whereas blocking the
production of new connexin molecules with protein synthesis inhibitors
leads to a gradual decline in the number of junctions. The rate of gap
junction loss in the latter case is, however, considerably slower than
would be expected from the half-life of connexins in untreated cells because of the inhibitory effect of protein synthesis blockers on
connexin turnover (see below). In assembly-inefficient cells, the
probability that a given connexin molecule will be assembled into a
plaque before it is degraded is relatively low. We propose that
decreasing the rate of connexin turnover with either proteasome inhibitors or protein synthesis blockers leads to a net increase in the
number of connexins available for assembly. Given the cooperative nature of insertion of functional intercellular channels into developing gap junctional plaques (53), even a modest elevation in cell
surface connexin levels could result in a rapid increase in gap
junction size. It is also conceivable that proteasome inhibitors and/or
protein synthesis inhibitors exert additional, less direct effects on
connexins in assembly-inefficient cells, such as activating signaling
events that promote gap junction formation. Despite increased Cx43
stability, assembly-incompetent L929 cells did not up-regulate gap
junctional plaques in response to either proteasome or protein
synthesis inhibitors. Although the basis for this behavior is not
known, it is possible that these cells are unable to form cell-cell
contacts permissive for gap junction assembly under the conditions
tested or are defective in some other aspect of junction establishment
or maintenance. A similar phenotype has been described for the human
colon tumor cell lines HT-29 and HCT-8, both of which remain
assembly-incompetent even after exogenous overexpression of wild-type
Cx43 (54).
Although pulse-chase analyses in a variety of systems have supported
the concept that connexins turn over rapidly, studies utilizing protein
synthesis inhibitors have lead to a very different view of connexin
stability. For example, Flagg-Newton et al. (55) have
reported that the number of gap junctional plaques detectable by
freeze-fracture electron microscopy in Balb-3T3 fibroblasts after a
24-h treatment with 10 µg/ml CHX was ~25% of that in untreated controls, which would correspond to a t1/2 of
12 h. Moreover, the gap junctions remaining were exceptionally large, leading to a less than 40% reduction in the gap junction area/µm2 of total cell surface. Similarly, Epstein
et al. (56) demonstrated that the capacity of Novikof
hepatoma cells to assemble endogenously expressed Cx43 into functional
gap junctions in a dissociation-reaggregation assay was only minimally
affected by a 12-h pretreatment with 100 µg/ml CHX. Our demonstration
that protein synthesis inhibitors decrease the rate of connexin
degradation provides an explanation for these previously puzzling
observations. Up-regulation of connexin stability and assembly is also
likely to have contributed to the unexpectedly long persistence of gap
junctional plaques in CHX-treated BICR-M1Rk cells reported
by Laird et al. (32). Such effects must be taken into
account in the interpretation of experiments conducted in the presence
of agents that inhibit protein synthesis as either their primary
activity or as a nonspecific side effect.
An important issue is the physiological significance of the ability of
inhibitors of protein synthesis and of the proteasome to up-regulate
gap junctions. Protein synthesis is greatly reduced in vivo
by starvation, viral infection, or exposure to certain metabolic
poisons, such as ricin and diphtheria toxin (57). Stabilization of
connexins under such conditions could facilitate cell-to-cell transfer
of metabolites and signaling molecules and might also serve to reduce
apoptosis of intercellular contact-dependent cells. A more
likely possibility is that inhibition of protein synthesis is an
experimental means to reduce the activity of the putative fast-turnover
mediator of connexin degradation and that the function of this protein
is normally controlled at the posttranslational level. A major goal of
future studies is to identify other effectors of connexin stability
that regulate intercellular communication in vivo.
 |
ACKNOWLEDGEMENTS |
We thank D. Goodenough (Harvard Medical
School) for providing anti-Cx32 antibodies and M. Bogyo (Harvard
Medical School) and D. Koop (Oregon Health Sciences University,
Portland, OR) for proteasome inhibitors.
 |
FOOTNOTES |
*
The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed: Vollum Institute for
Advanced Biomedical Research L474, Oregon Health Sciences University,
3181 Southwest Sam Jackson Park Rd., Portland, OR 97201. Tel.:
503-494-1300; Fax: 503-494-8230; E-mail: Musill@ohsu.edu.
Published, JBC Papers in Press, June 2, 2000, DOI 10.1074/jbc.M002608200
 |
ABBREVIATIONS |
The abbreviations used are:
Cx43, connexin43;
Cx32, connexin32;
NRK, normal rat kidney;
ssS180L, serum-starved S180L;
ZL3VS, carboxybenzyl-leucyl-leucyl-leucine vinylsulfone;
ALLN, N-acetyl-leu-leu-norleucinal;
DTT, dithiothreitol;
LY, Lucifer Yellow;
CLQ, chloroquine;
CHX, cycloheximide;
CHO, Chinese
hamster ovary;
DMEM, Dulbecco's modified Eagle's medium;
FCS, fetal
calf serum;
PBS, phosphate-buffered saline;
HB, Hanks' balanced salt
solution containing 1% bovine serum albumin.
 |
REFERENCES |
| 1.
|
Goodenough, D. A.,
Goliger, J. A.,
and Paul, D. L.
(1996)
Annu. Rev. Biochem.
65,
475-502
|
| 2.
|
Musil, L. S.
(1994)
in
Molecular Mechanisms of Epithelial Cell Junctions: From Development to Disease
(Citi, S., ed)
, pp. 173-194, R. G. Landes, Austin, TX
|
| 3.
|
Hare, J.,
and Taylor, K.
(1991)
Proc. Natl. Acad. Sci. U. S. A.
88,
5902-5906
|
| 4.
|
Musil, L. S.,
Cunningham, B. A.,
Edelman, G. M.,
and Goodenough, D. A.
(1990)
J. Cell Biol.
111,
2077-2088
|
| 5.
|
Traub, O.,
Look, J.,
Dermietzel, R.,
Brummer, F.,
Hulser, D.,
and Willecke, K.
(1989)
J. Cell Biol.
108,
1039-1051
|
| 6.
|
Beardslee, M. A.,
Laing, J. G.,
Beyer, E. C.,
and Saffitz, J. E.
(1998)
Circ. Res.
83,
629-635
|
| 7.
|
Fallon, R. F.,
and Goodenough, D. A.
(1981)
J. Cell Biol.
90,
521-526
|
| 8.
|
Wong, V.,
and Gumbiner, B. M.
(1997)
J. Cell Biol.
136,
399-409
|
| 9.
|
Penn, E. J.,
Burdett, I. D.,
Hobson, C.,
Magee, A. I.,
and Rees, D. A.
(1987)
J. Cell Biol.
105,
2327-2334
|
| 10.
|
Larsen, W. J.,
and Tung, H. N.
(1978)
Tissue Cell
10,
585-598
|
| 11.
|
Laing, J. G.,
and Beyer, E. C.
(1995)
J. Biol. Chem.
270,
26399-26403
|
| 12.
|
Laing, J. G.,
Tadros, P. N.,
Westphale, E. M.,
and Beyer, E. C.
(1997)
Exp. Cell Res.
236,
482-492
|
| 13.
|
VanSlyke, J. K.,
Deschenes, S. M.,
and Musil, L. S.
(2000)
Mol. Biol. Cell
11,
1933-1946
|
| 14.
|
Bonifacino, J. S.,
and Weissman, A. M.
(1998)
Annu. Rev. Cell Dev. Biol.
14,
19-57
|
| 15.
|
Ciechanover, A.,
Laszlo, A.,
Bercovich, B.,
Stancovski, I.,
Alkalay, I.,
Ben-Neriah, Y.,
and Orian, A.
(1995)
Cold Spring Harbor Symp. Quant. Biol.
60,
491-501
|
| 16.
|
Thrower, J. S.,
Hoffman, L.,
Rechsteiner, M.,
and Pickart, C. M.
(2000)
EMBO J.
19,
94-102
|
| 17.
|
Pahl, H. L.,
and Baeuerle, P. A.
(1996)
Curr. Opin. Cell Biol.
8,
340-347
|
| 18.
|
Glass, J. R.,
and Gerner, E. W.
(1987)
J. Cell. Physiol.
130,
133-141
|
| 19.
|
Murakami, Y.,
Tanahashi, N.,
Tanaka, K.,
Omura, S.,
and Hayashi, S.
(1996)
Biochem. J.
317,
77-80
|
| 20.
|
Ziemiecki, A.,
Friis, R. R.,
and Bauer, H.
(1982)
Mol. Cell. Biol.
2,
355-360
|
| 21.
|
Borras, M.,
Laios, I.,
el Khissiin, A.,
Seo, H. S.,
Lempereur, F.,
Legros, N.,
and Leclercq, G.
(1996)
J. Steroid Biochem. Mol. Biol.
57,
203-213
|
| 22.
|
Reich, N. C.,
Oren, M.,
and Levine, A. J.
(1983)
Mol. Cell. Biol.
3,
2143-2150
|
| 23.
|
Mege, R. M.,
Matsuzaki, F.,
Gallin, W. J.,
Goldberg, J. I.,
Cunningham, B. A.,
and Edelman, G. M.
(1988)
Proc. Natl. Acad. Sci. U. S. A.
85,
7274-7278
|
| 24.
|
Deschenes, S. M.,
Walcott, J. L.,
Wexler, T. L.,
Scherer, S. S.,
and Fischbeck, K. H.
(1997)
J. Neurosci.
17,
9077-9084
|
| 25.
|
Goodenough, D. A.,
Paul, D. L.,
and Jesaitis, L.
(1988)
J. Cell Biol.
107,
1817-1824
|
| 26.
|
Le, A. C.,
and Musil, L. S.
(1998)
Dev. Biol.
204,
80-96
|
| 27.
|
el-Fouly, M. H.,
Trosko, J. E.,
and Chang, C. C.
(1987)
Exp. Cell Res.
168,
422-430
|
| 28.
|
Venance, L.,
Piomelli, D.,
Glowinski, J.,
and Giaume, C.
(1995)
Nature
376,
590-594
|
| 29.
|
VanSlyke, J. K.,
and Musil, L. S.
(2000)
Methods
20,
156-164
|
| 30.
|
Musil, L. S.,
and Goodenough, D. A.
(1991)
J. Cell Biol.
115,
1357-1374
|
| 31.
|
Musil, L. S.,
and Goodenough, D. A.
(1993)
Cell
74,
1065-1077
|
| 32.
|
Laird, D. W.,
Castillo, M.,
and Kasprzak, L.
(1995)
J. Cell Biol.
131,
1193-1203
|
| 33.
|
Steinbach, J. H.,
Merlie, J.,
Heinemann, S.,
and Bloch, R.
(1979)
Proc. Natl. Acad. Sci. U. S. A.
76,
3547-3551
|
| 34.
|
Chang, C. C.,
and Huang, M. C.
(1975)
Nature
253,
643-644
|
| 35.
|
Nagy, J. I.,
Li, W. E.,
Roy, C.,
Doble, B. W.,
Gilchrist, J. S.,
Kardami, E.,
and Hertzberg, E. L.
(1997)
Exp. Cell Res.
236,
127-136
|
| 36.
|
Lee, D. H.,
and Goldberg, A. L.
(1998)
Trends Cell. Biol.
8,
397-403
|
| 37.
|
Fritsch, J. E.,
Buckmaster, M. J.,
and Storrie, B.
(1988)
Exp. Cell Res.
175,
277-285
|
| 38.
|
Foote, C. I.,
Zhou, L.,
Zhu, X.,
and Nicholson, B. J.
(1998)
J. Cell Biol.
140,
1187-1197
|
| 39.
|
Krutovskikh, V.,
Mazzoleni, G.,
Mironov, N.,
Omori, Y.,
Aguelon, A. M.,
Mesnil, M.,
Berger, F.,
Partensky, C.,
and Yamasaki, H.
(1994)
Int. J. Cancer
56,
87-94
|
| 40.
|
Valdimarsson, G.,
De Sousa, P. A.,
Beyer, E. C.,
Paul, D. L.,
and Kidder, G. M.
(1991)
Mol. Reprod. Dev.
30,
18-26
|
| 41.
|
Hendrix, E. M.,
Mao, S. J.,
Everson, W.,
and Larsen, W. J.
(1992)
Mol. Reprod. Dev.
33,
27-38
|
| 42.
|
Jensen, T. J.,
Loo, M. A.,
Pind, S.,
Williams, D. B.,
Goldberg, A. L.,
and Riordan, J. R.
(1995)
Cell
83,
129-135
|
| 43.
|
Yang, M.,
Omura, S.,
Bonifacino, J. S.,
and Weissman, A. M.
(1998)
J. Exp. Med.
187,
835-846
|
| 44.
|
Guo, B.,
Phillips, J. D., Yu, Y.,
and Leibold, E. A.
(1995)
J. Biol. Chem.
270,
21645-21651
|
| 45.
|
Wileman, T.,
Carson, G. R.,
Shih, F. F.,
Concino, M. F.,
and Terhorst, C.
(1990)
Cell Regul.
1,
907-919
|
| 46.
|
Boundy, V. A.,
Chen, J.,
and Nestler, E. J.
(1998)
J. Pharmacol. Exp. Ther.
286,
1058-1065
|
| 47.
|
Howe, J. A.,
Howell, M.,
Hunt, T.,
and Newport, J. W.
(1995)
Genes Dev.
9,
1164-1176
|
| 48.
|
Seglen, P. O.
(1983)
Methods Enzymol.
96,
737-764
|
| 49.
|
Pickart, C. M.
(1997)
FASEB J.
11,
1055-1066
|
| 50.
|
Yu, H.,
and Kopito, R. R.
(1999)
J. Biol. Chem.
274,
36852-36858
|
| 51.
|
El Khissiin, A.,
and Leclercq, G.
(1999)
FEBS Lett.
448,
160-166
|
| 52.
|
Rook, M. B.,
de Jonge, B.,
Jongsma, H. J.,
and Masson-Pevet, M. A.
(1990)
J. Membr. Biol.
118,
179-192
|
| 53.
|
Castro, C.,
Gomez-Hernandez, J. M.,
Silander, K.,
and Barrio, L. C.
(1999)
J. Neurosci.
19,
3752-3760
|
| 54.
|
McMasters, R. A.,
Saylors, R. L.,
Jones, K. E.,
Hendrix, M. E.,
Moyer, M. P.,
and Drake, R. R.
(1998)
Hum. Gene Ther.
9,
2253-2261
|
| 55.
|
Flagg-Newton, J. L.,
Dahl, G.,
and Loewenstein, W. R.
(1981)
J. Membr. Biol.
63,
105-121
|
| 56.
|
Epstein, M. L.,
Sheridan, J. D.,
and Johnson, R. G.
(1977)
Exp. Cell Res.
104,
25-30
|
| 57.
|
Hinnebusch, A. G.
(1994)
Semin. Cell Biol.
5,
417-426
|
Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
X. Li, V. Su, W. E. Kurata, C. Jin, and A. F. Lau
A Novel Connexin43-interacting Protein, CIP75, Which Belongs to the UbL-UBA Protein Family, Regulates the Turnover of Connexin43
J. Biol. Chem.,
February 29, 2008;
283(9):
5748 - 5759.
[Abstract]
[Full Text]
[PDF]
|
 |
|